These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16341747)

  • 1. When do children convert from liquid antiretroviral to solid formulations?
    Yeung VW; Wong IC
    Pharm World Sci; 2005 Oct; 27(5):399-402. PubMed ID: 16341747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
    Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contraindicated antiretroviral drug combinations.
    Macher A; Thomas D; Paul SM
    N J Med; 2003 Sep; 100(9 Suppl):41-3; quiz 73-4. PubMed ID: 14556602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Rao Thudi N; Koundinya Tippabhotla S; Khuroo A; Marwah A; Kumar Shrivastav V; Tandon M; Raghuvanshi R; Biswal S
    Clin Ther; 2007 Dec; 29(12):2677-84. PubMed ID: 18201583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
    Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
    N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
    Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
    AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
    Verweij-van Wissen CP; Aarnoutse RE; Burger DM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):121-9. PubMed ID: 15664342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011.
    Shen Y; Wang J; Qi T; Wang Z; Lu H
    Int J STD AIDS; 2014 Jun; 25(7):504-10. PubMed ID: 24327726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of a protease inhibitor-sparing, nucleoside reverse transcriptase inhibitor-limiting antiretroviral regimen with nevirapine, lamivudine, and reduced standard stavudine dosage.
    Shalit P; Farrell P; McClarty M
    HIV Clin Trials; 2004; 5(1):62-4. PubMed ID: 15002088
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
    Dubé MP; Parker RA; Mulligan K; Tebas P; Robbins GK; Roubenoff R; Grinspoon SK
    Clin Infect Dis; 2007 Jul; 45(1):120-6. PubMed ID: 17554712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
    Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E
    Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
    Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Primary results of antiretroviral treatment among HIV/AIDS infected children in Lomé (Togo)].
    Atakouma DY; Tsolenyanu E; Gbadoe A; Gbetoglo V; Lawson-Evi K; Agbere AR; Tatagan-Agbi K; Assimadi K
    Arch Pediatr; 2007 Oct; 14(10):1178-82. PubMed ID: 17531452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Taejaroenkul S; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2012 Apr; 31(4):384-8. PubMed ID: 22124211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
    Eiros Bouza JM; Ortega Lafont M; Ortiz de Lejarazu R; Bachiller Luque P; de Luis Román DA
    An Med Interna; 2003 May; 20(5):239-42. PubMed ID: 12831297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.
    de Mendoza C; Ramos JT; Ciria L; Fortuny C; García FJ; de José MI; Asensi F; Soriano V
    HIV Clin Trials; 2002; 3(1):9-16. PubMed ID: 11819180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.